Constructive Bio Strengthens Leadership Team with Appointment of Dr Bill Eldridge as Vice President of Biologics

Constructive Bio, a leader in synthetic biology and genome engineering, today announces the appointment of Dr Eldridge as Vice President of Biologics. Dr Eldridge joins at a pivotal moment for Constructive Bio as it accelerates its transition from groundbreaking research to impactful commercial solutions.

With over 25 years of expertise in peptides and biologics engineering, Dr Eldridge has a proven track record in drug discovery and development, contributing to the invention of multiple platform technologies and holding numerous patents in the protein and peptide space. During his career, he has led strategic discovery and development programmes, with a particular focus on harnessing non-natural amino acids—a core area of Constructive Bio’s work. Dr Eldridge previously served at Isogenica, where he advanced platform technologies and steered product development to market readiness. His appointment underscores Constructive Bio’s commitment to assembling a world-class team capable of transforming cutting-edge science into tangible outcomes.

“Bill’s achievements in developing platform technologies that yield new assets speak for themselves,” said Dr Ola Wlodek, CEO of Constructive Bio. “He will play a pivotal role in bridging groundbreaking research and commercial success through the development of transformative therapeutic products. We are excited to welcome him to the team and look forward to the impact he will make as we scale our innovations to meet significant industry demand.”

“Constructive Bio is at the forefront of a biotech revolution,” said Dr Eldridge. “The breakthroughs the team have achieved in genome synthesis are already transforming pharmaceutical manufacturing and will forever change drug discovery. I’m thrilled to help accelerate its commercial applications and create real-world impact.”

This strategic hire comes during an exciting period of rapid growth for Constructive Bio, following its successful Series A funding round of $58 million and the addition of Nobel laureate Sir Gregory Winter to its board of directors. Constructive Bio’s technology platform, which enables the development of engineered proteins and peptides with unprecedented precision, is poised to redefine drug development and discovery.

About Constructive Bio

At Constructive Bio we rewrite the genome to build the biomolecules of the future. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.

Through exclusive access to breakthrough science from the MRC Laboratory of Molecular Biology, based on the research carried out by our founder Professor Jason Chin, Constructive Bio alone has the ability to rewrite entire genomes and incorporate multiple non-canonical amino acids in a single molecule.

Constructive Bio is realising the full scientific and commercial potential of its technologies through its proprietary platforms. These include:

Full genome synthesis: We assemble DNA into genome-scale pieces, stitching and replacing megabases of DNA inside living cells. Through this process, we create entirely new genomes from scratch, writing the genetic blueprint of cells with unprecedented flexibility and precision.

Engineered protein translation: Constructive Bio synthesises proteins with expanded functions by incorporating non-canonical amino acids (ncAAs). Through reprogramming the genetic code of cells and expanding their repertoire of chemical building blocks, our technology creates biofactories for the discovery and manufacturing of novel biopolymers. These molecules have unique properties and diverse applications across science and industry, including pharmaceuticals, agriculture and biomaterials.

Contact

Emma Kosian

+447444840575

e.kosian@hawthornadvisors.com